Showing results (201-210 of 224) with videos related to
Sort By:
Pageof 23
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|October 16, 2023
Effect of elexacaftor/tezacaftor/ivacaftor on mucus and mucociliary clearance in cystic fibrosisScott H Donaldson, Timothy E Corcoran, Joseph M Pilewski, et al.The Lancet. Respiratory Medicine|August 2, 2025
Maximising opportunity for therapeutic success: sequential participation in cystic fibrosis nucleic acid-based therapy trialsNicole Mayer-Hamblett, Natanya R Kerper, John P Clancy, et al.JCI Insight|December 21, 2018
Effect of ivacaftor on mucociliary clearance and clinical outcomes in cystic fibrosis patients with G551D-CFTRScott H Donaldson, Beth L Laube, Timothy E Corcoran, et al.Annals of the American Thoracic Society|January 19, 2021
Evaluating the Impact of Stopping Chronic Therapies after Modulator Drug Therapy in Cystic Fibrosis: The SIMPLIFY Clinical Trial Study DesignNicole Mayer-Hamblett, David P Nichols, Katherine Odem-Davis, et al.Journal of Medicinal Chemistry|January 25, 2002
Synthesis and evaluation of potent and selective beta(3) adrenergic receptor agonists containing acylsulfonamide, sulfonylsulfonamide, and sulfonylurea carboxylic acid isosteresDavid E Uehling, Kelly H Donaldson, David N Deaton, et al.Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|January 30, 2026
Longitudinal changes in bone mineral density after initiation of elexacaftor-tezacaftor-ivacaftor in youth and adults with cystic fibrosis: PROMISE-ENDOMeghan Shirley Bezerra, Babette S Zemel, Robert J Gallop, et al.American Journal of Respiratory and Critical Care Medicine|September 14, 2018
An Improved Inhaled Mucolytic to Treat Airway Muco-obstructive DiseasesCamille Ehre, Zachary L Rushton, Boya Wang, et al.The Journal of Clinical Endocrinology and Metabolism|December 10, 2024
Glycemia and Insulin Secretion in Cystic Fibrosis Two Years After Elexacaftor/Tezacaftor/Ivacaftor: PROMISE-ENDOChristine L Chan, Meghan Shirley Bezerra, Darko Stefanovski, et al.Bioorganic & Medicinal Chemistry Letters|December 30, 2008
Thienopyrimidine-based dual EGFR/ErbB-2 inhibitorsTara R Rheault, Thomas R Caferro, Scott H Dickerson, et al.Journal of Medicinal Chemistry|April 28, 2006
Biarylaniline phenethanolamines as potent and selective beta3 adrenergic receptor agonistsDavid E Uehling, Barry G Shearer, Kelly H Donaldson, et al.Pageof 23